Sarepta Gene Therapy Risks

News

Sarepta, gene therapy

Sarepta shares plunge 40% as future of its gene therapy appears at risk

Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its key gene therapy treatment appeared at risk. The Food and Drug Administration will request that the company voluntarily stop all shipments of the treatment, Elevidys, a person familiar with the matter told CNBC.

· 2d · on MSN

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys

BioPharma Dive · 2d

Sarepta reports patient death in limb-girdle trial, compounding concerns on gene therapy risks

58m

Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys

FDA places clinical hold on Sarepta's LGMD gene therapy trials after three deaths and revokes platform tech designation due ...

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

Also on Friday, the Food and Drug Administration informally requested that Sarepta voluntarily pause shipments of another gene therapy, Elevidys, which is approved to treat a different type of ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

Sarepta, gene therapy

Trending now